Temoporfin
- Generic Name
- Temoporfin
- Brand Names
- Foscan
- Drug Type
- Small Molecule
- Chemical Formula
- C44H32N4O4
- CAS Number
- 122341-38-2
- Unique Ingredient Identifier
- FU21S769PF
- Background
Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck . It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
- Indication
For use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy, surgery, or systemic chemotherapy .
- Associated Conditions
- Advanced squamous cell carcinoma of the head and neck
- Associated Therapies
- -
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 10
- Registration Number
- NCT03003065
- Locations
- ðŸ‡ðŸ‡°
Endoscopy Centre, Prince of Wales Hospital, Shatin, N.t., Hong Kong
Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT01854684
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer
- Conditions
- Recurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Verrucous Carcinoma of the Oral CavityStage II Verrucous Carcinoma of the Oral CavityStage I Squamous Cell Carcinoma of the Lip and Oral CavityStage I Verrucous Carcinoma of the Oral CavityTongue CancerRecurrent Squamous Cell Carcinoma of the OropharynxStage I Squamous Cell Carcinoma of the OropharynxStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage II Squamous Cell Carcinoma of the Oropharynx
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT01718223
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
- Conditions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT01637376
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 1
- Registration Number
- NCT01415986
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- University of Salzburg
- Target Recruit Count
- 35
- Registration Number
- NCT01016002
- Locations
- 🇩🇪
Internal Medicine Dept., University Medical Center Hamburg-Eppendorf, Hamburg, Germany
🇦🇹Department of Internal Medicine I, Paracelsus Medical University Salzburg, Salzburg, Austria
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Quintiles, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00003856
- Locations
- 🇺🇸
St. Luke's-Roosevelt Hospital, New York, New York, United States
🇺🇸School of Dental Medicine, Buffalo, New York, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.